Form 4: Madrigal Pharmaceuticals Director Sells Shares in Multiple Transactions

Madrigal Pharmaceuticals director Fred B. Craves sold a portion of his holdings in multiple transactions on December 3, 2024.

Summary

• Fred B. Craves, a director at Madrigal Pharmaceuticals, sold 3,080 shares of common stock at a weighted average price of $315.2116 on December 3, 2024.
• He also sold 520 shares of common stock at a weighted average price of $315.9038 on the same day.
• These transactions reduced his direct holdings but he still maintains indirect ownership through various entities.
• The sales were executed in multiple transactions with prices ranging from $315.00 to $315.73 for the first sale and $315.84 to $316.16 for the second sale.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock sales by a director, with no indication of positive or negative sentiment.

Industry Context

This is a routine SEC Form 4 filing, which is common for corporate insiders who trade company stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transactions are typical for directors managing their personal portfolios and are not unusual in the context of the broader market.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price, but are unlikely to have a significant effect on other stakeholders.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, insider trading, stock sale, Fred B. Craves, director, share transaction